Skip to main content
Springer logoLink to Springer
. 2023 Sep 16;93(5):523. doi: 10.1007/s00280-023-04587-8

Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

Mototsugu Oya 1, Shuichi Kaneko 2, Tsuneo Imai 3, Toshiaki Tsujino 4, Toshiyuki Sunaya 5, Yutaka Okayama 4,
PMCID: PMC11043094  PMID: 37715787

Retraction Note: Cancer Chemotherapy and Pharmacology (2022) 89:761-772 10.1007/s00280-022-04428-0

The Authors have retracted this article. After publication the authors found a flaw in the way the raw data was handled for this study and found that the data analysis was incomplete. The authors re-analysed the data and found that the conclusions initially drawn from the results were no longer supported. The authors, therefore, no longer have confidence in the results presented in this article. All authors agree to this retraction.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Cancer Chemotherapy and Pharmacology are provided here courtesy of Springer

RESOURCES